Literature DB >> 20227774

Sensorineural deafness in Tanzanian children--is ototoxicity a significant cause? A pilot study.

Andrew Freeland1, Jane Jones, Naufal Kassim Mohammed.   

Abstract

OBJECTIVES: 9 years experience working in Tanzania revealed a surprisingly large population of profoundly deaf children. The object was to identify the cause.
METHODS: 200 children between the ages of 5-12 with significant sensorineural hearing loss were identified in Stone town, Zanzibar. These were aged and neighbourhood matched with 218 normal hearing children. A parental questionnaire administered by health workers from the Zanzibar Outreach Programme was used to interview parents of the matched group of deaf and normal hearing children. Outcome measures included the genetic history especially first cousin marriage (common in Zanzibar), rubella, head injury, fever admission, and drug treatment of fever. The limitations were lack of hospital records and it was a retrospective study. The results were analysed from Excel spreadsheets.
RESULTS: 36% of the deaf group had an infant fever admission history compared with 4% of the normal hearing group. Nearly all had i.m. quinine and/or gentamicin. The genetic history was equal in both groups, and rubella was rare. Most fevers were assumed to be malaria or pneumonia which are unlikely causes of deafness on their own.
CONCLUSIONS: Ototoxic drugs given to sick infants with "fever", without weight recording or gentamicin level monitoring, was the probable cause of a third of all severe/profound deafened Zanzibarian children. The Ministry of Health and Social Welfare in Zanzibar have reacted by issuing posters to all health facilities advising hearing testing in all children three months after discharge following "fever" admission. This is a pilot study and the apparent findings need to be confirmed by a well designed prospective study as soon as possible. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227774     DOI: 10.1016/j.ijporl.2010.02.010

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  5 in total

Review 1.  The role of the health system in the prevention of hearing loss among children in Sub-Saharan Africa.

Authors:  Fayrouz Mohammed Abdalla; Mayeh Abu Omar
Journal:  Sudan J Paediatr       Date:  2011

2.  Evaluation of Gentamicin Exposure in the Neonatal Intensive Care Unit and Hearing Function at Discharge.

Authors:  Mihai Puia-Dumitrescu; Olivia M Bretzius; Nia Brown; James A Fitz-Henley; Rebecca Ssengonzi; Caroline S Wechsler; Keyaria D Gray; Daniel K Benjamin; P Brian Smith; Reese H Clark; Daniel Gonzalez; Christoph P Hornik
Journal:  J Pediatr       Date:  2018-09-21       Impact factor: 4.406

3.  Apoptosis of the fibrocytes type 1 in the spiral ligament and blood labyrinth barrier disturbance cause hearing impairment in murine cerebral malaria.

Authors:  Joachim Schmutzhard; Christian H Kositz; Rudolf Glueckert; Erich Schmutzhard; Annelies Schrott-Fischer; Peter Lackner
Journal:  Malar J       Date:  2012-02-01       Impact factor: 2.979

4.  Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions--a prospective multicenter cohort study.

Authors:  Joachim Schmutzhard; Peter Lackner; Raimund Helbok; Helene Verena Hurth; Fabian Cedric Aregger; Veronika Muigg; Josua Kegele; Sebastian Bunk; Lukas Oberhammer; Natalie Fischer; Leyla Pinggera; Allan Otieno; Bernards Ogutu; Tsiri Agbenyega; Daniel Ansong; Ayola A Adegnika; Saadou Issifou; Patrick Zorowka; Sanjeev Krishna; Benjamin Mordmüller; Erich Schmutzhard; Peter Kremsner
Journal:  BMC Med       Date:  2015-05-28       Impact factor: 8.775

Review 5.  Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

Authors:  F A Diepstraten; A E Hoetink; M van Grotel; A D R Huitema; R J Stokroos; M M van den Heuvel-Eibrink; A J M Meijer
Journal:  JAC Antimicrob Resist       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.